The $136.8 billion revenue drug wholesaler and medical supplier managed 5.3% sales growth in 2018 despite an increasingly challenging environment largely due to greater sales of high-price drugs used in oncology, among other medical specialties. The bulk of Cardinal’s revenue comes from the medications it distributes to pharmacies and is impacted by fluctuations in drug prices. The declining price of generics has weighed on the company's bottom line in recent years and the heightened scrutiny of drug pricing has created uncertainty for Cardinal and its two bigger rivals, McKesson and AmerisourceBergen. The industry is also under continued pressure—and faces a growing number of lawsuits—over its alleged role in the nation’s opioid epidemic.
Company Info
| CEO | Michael C. Kaufmann |
| CEO Title | Chairman & Chief Executive Officer |
| Sector | Health Care |
| Industry | Wholesalers: Health Care |
| HQ Location | Dublin, Ohio |
| Website | www.cardinalhealth.com |
| Years on Fortune 500 List | 25 |
| Employees | 50,200 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $136,809 |
| Profits ($M) | $256 |
| Assets ($M) | $39,951 |
| Total Stockholder Equity ($M) | $6,059 |
Profit Ratios
| Profit as % of Revenues | 0.2% |
| Profits as % of Assets | 0.6% |
| Profits as % of Stockholder Equity | 4.2% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 81 |
| EPS % Change (from 2017) | -79.9% |
| EPS % Change (5 year annual rate) | -3.5% |
| EPS % Change (10 year annual rate) | -13.8% |
Total Return
| Total Return to Investors (2018) | -24.8% |
| Total Return to Investors (5 year, annualized) | -5.6% |
| Total Return to Investors (10 year, annualized) | 8.4% |
